Excessive sleep associated with longer time to return to work among colorectal cancer survivors
the ONA take:
Excessive sleep was associated with a longer time to return to work, a reduction in work time, and increased likelihood to retire among colorectal cancer survivors, according to a recent study published online ahead of print in the journal Supportive Care in Cancer.
For the study, researchers in Australia enrolled 239 colorectal cancer survivors in order to assess associations of health behaviors with return to work outcomes following a colorectal cancer diagnosis among men and women aged 45 to 64 years. Participants were interviewed via telephone and answered questionnaires at 6 and 12 months following diagnosis.
Results showed that participants who reported sleeping 9 or more hours per day were 2.69 times more likely to decrease work time or retire compared with those who slept between 7 and 9 hours per day. Researchers found that excessive sleep was also associated with a longer time to returning to work.
The findings suggest that interventions designed to help colorectal cancer survivors achieve optimal sleep may help them return to work sooner. Further studies are warranted to test those interventions.
Excessive sleep was associated with a longer time to return to work, a reduction in work time, and increased likelihood to retire.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|